Independent fund research. Built on SEC filings.

How we research funds

ETF · Large Blend · Innovator

Tema Oncology ETF (CANC)

Ticker CANC · Since 2023-08-15 · · Holdings as of May 31, 2026

Expense ratio
0.75%$75/yr per $10k
1-yr return
+42.8%as of Dec 2025
Net assets
$176.1Mall share classes
Holdings
57

Bottom line

Is CANC a good fund? The bottom line

CANC is an actively managed large blend ETF from Innovator.

Annual fees run 0.75% — about $75 a year on every $10,000 invested, cheaper than 55% of large blend funds we track.

It returned +42.8% over one year (as of Dec 31, 2025, per its prospectus).

With $176 million in net assets and 57 holdings, its largest position is Revolution Medicines Inc (7.7%) and the top 10 make up 42.9% of the portfolio.

Updated Nov 19, 2026

What CANC invests in

Tema Oncology ETF (the Fund) seeks to provide long-term growth.

Under normal circumstances, the Fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The Tema ETF LLC (the Adviser), the Funds investment adviser, will use internal research and analysis based on company disclosure (such as 10-K filings, company presentations, capital markets day presentations) and other publicly available sources (e.g., sell-side research, biotechnology industry publications etc.) to make this assessment. Example companies include large pharmaceutical firms, diagnostic focused businesses with products used to diagnose cancer (such as liquid biopsies or cancer genomic screening), medical device companies focused on cancer treatment, and healthcare service providers with a specific strategic focus on…

From the fund's prospectus (filed Jun 29, 2026).

CANC performance

Fund calendar-year total returns, 2024–2025 2024: −5.3%; 2025: +42.8% −5.3% 2024 +42.8% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
CANC+42.8%——
Large Blend median+13.8%+9.7%+10.9%

Source: Fund prospectus, as of Dec 31, 2025

Full CANC performance history →

What CANC costs

On a $10,000 investment, CANC's 0.75% expense ratio costs about $75 a year. The prospectus estimates $1,168 in total costs over 10 years (assuming 5% annual returns). The median large blend fund charges 0.83%.

See the full CANC fee table →

CANC top 10 holdings

#Holding% of fund
1Revolution Medicines Inc RVMD7.73%
2Eli Lilly & Co LLY4.82%
3Roche Holding AG RHHBY4.21%
4Cogent Biosciences Inc COGT4.10%
5Novartis AG NOVN4.03%
6Immunome Inc IMNM3.91%
7Celcuity Inc CELC3.58%
8Merck & Co Inc MRK3.57%
9AstraZeneca PLC AZN3.54%
10Nuvalent Inc NUVL3.37%

Source: SEC Form N-PORT, period ended May 31, 2026

The top 10 make up 42.9% of the fund. See all top 25 holdings and asset mix →

Alternatives to CANC

More funds like CANC →

CANC FAQ

What is the expense ratio of CANC?
CANC's expense ratio is 0.75%, which works out to about $75 a year for every $10,000 invested. The prospectus estimates total costs of $1,168 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is CANC a good investment?
It depends on your goals, but the data points to: a typical fund for its category. This is general information, not personalized advice.
What does CANC hold?
CANC's largest holdings are Revolution Medicines Inc (7.7%), Eli Lilly & Co (4.8%), Roche Holding AG (4.2%), Cogent Biosciences Inc (4.1%), Novartis AG (4.0%). It holds 57 positions in total as of May 31, 2026 (SEC Form N-PORT).
Who manages CANC?
CANC is offered by Innovator through Tema ETF Trust.